Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Professorial Research Fellow
- Research Department of Haematology
- Cancer Institute
- Faculty of Medical Sciences
Dr. Quezada earned an undergraduate degree in biochemistry from the P. Universidad Católica de Chile and a Ph.D. from Dartmouth Medical School, where his research focused on the mechanisms for the induction of transplantation tolerance. Working with Dr. Randy Noelle at Dartmouth, Dr. Quezada developed a model to study anti-CD154 graft tolerance and made several fundamental contributions to the understanding of the immune regulation and mechanisms of transplantation rejection and tolerance.
In 2004, Dr. Quezada joined the laboratory of Dr. James Allison at Memorial Sloan-Kettering Cancer Center, where he has carried out postdoctoral research aimed at understanding the mechanisms governing anti-tumor T-cell immunity and how these mechanisms can be manipulated for the generation of potent anti-tumor immune responses. In November 2011, Dr. Quezada joined the University College London Cancer Institute in the United Kingdom as head of the Immune Regulation and Tumor Immunotherapy group.
A Cancer Research Institute fellow from 2005 to 2008, Dr. Quezada has also been the recipient of a John W. Strohbern Medal, the Sunny-Plattsburgh Basic Science Research Fellowship, and, most recently, the CRUK Career Development Fellowship. Since 2006, Dr. Quezada has been a young investigator member of the Millennium Nucleus on Immunology and Immunotherapy of the Chilean Ministry of Planning and has served as an external evaluator for the Chilean National Science and Technology Research Fund.
Our group uses transplantable and autochthonous mouse models of cancer to investigate the in vivo interplay between the immune system and cancer throughout tumour progression and immunotherapy. Our aim to identify and target the most relevant cellular and molecular pathways restricting the activation of tumour-reactive lymphocytes, their access to the tumour site, and their activity within the tumour microenvironment.
Specifically, we are interested in how the function and plasticity of tumour-reactive CD4 T cells is regulated by the tumour microenvironment and by immune co-inhibitory (e.g. CTLA-4 and PD-1) and co-stimulatory signals (e.g. GITR, OX40, CD27). As well, we are interested in understanding how these regulatory circuits control the efficacy of cellular vaccination and adoptive cell transfer strategies and how can they be manipulated to induce potent antitumor immunity.
Data obtained from these studies will not only inform the basic understanding of the immune response to malignancies but, in the context of the UCL Cancer Institute, will be used as a platform for the development of novel translational strategies in the clinic.
|2004||PhD||Doctor of Philosophy – Immunology||Dartmouth College, Hanover|
|1998||BSc||Bachelor of Science – Biochemistry||Pontificia Universidad Católica de Chile|